Press Releases

BOSTON and SYDNEY — 20 September 2018— GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary...

BOSTON and SYDNEY – 15 August 2018 – GI Dynamics Inc. (ASX: GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, announces it will update shareholders on 2018 second quarter results as reported on Form 10Q for the three and...

Pivotal trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity • Primary Endpoint        Reduction of HbA1c at 1 year • Planned Study Size                                           Stage I: 50 EndoBarrier / 17 control                                  ...

BOSTON and SYDNEY — 9 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients diagnosed with type 2 diabetes and obesity, is pleased to announce the first report from the Association of British Clinical Diabetologists (ABCD) Worldwide...

BOSTON and SYDNEY — 4 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce further positive results from the ongoing National Health Service (NHS) EndoBarrier Service in the U.K.,...

BOSTON and SYDNEY – 31 May 2018 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to confirm that, further to the Company’s announcement on 2 May 2018, it has completed the US$1,750,000 convertible note...

BOSTON and SYDNEY — 16 May 2018 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2018 Annual Meeting of Stockholders on 24 May 2018 at 6:00 pm United States Eastern Daylight Time, (which is 25 May 2018 at 8:00 am Australian Eastern Standard Time), at the offices of Mintz, Levin, Cohn,...

BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...

BOSTON and SYDNEY – 2 May 2018 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has received a binding commitment for a US$1,750,000 convertible note and warrant financing from Crystal Amber Fund Limited. The...

BOSTON and SYDNEY – 28 March 2018 – GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announced that it will release its 2017 Annual Report on Form 10K on or before 31 March EDT | 1 April AEST 2018. GI Dynamics...